For the first time, the Brazilian Football Confederation (CBF) joins Angelman Brasil in a national awareness campaign about Angelman Syndrome, a rare and still little-known genetic condition. The ...
Though their bright smiles and arm-flapping exuberance suggests otherwise, victims of Angelmans Syndrome is so serious one South Side couple has started a non-profit to teach others about the rare ...
NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE), today announced that the first patient has been dosed in the pivotal Phase 3 Aspire study (NCT06617429) ...
Company expects to complete Phase 3 Aspire study in the second half of 2026 Aurora study of GTX-102 in additional ages and genotypes on track to initiate in the second half of 2025 “The accelerated ...
Ultragenyx Pharmaceutical Inc. announced the dosing of the first patient in its Phase 3 Aspire study, which is investigating the safety and efficacy of GTX-102, an investigational antisense ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results